Amgen Inc. (NASDAQ:AMGN)‘s stock had its “overweight” rating restated by investment analysts at Morgan Stanley in a report issued on Monday.

Other analysts also recently issued research reports about the stock. Goldman Sachs Group, Inc. (The) dropped their target price on shares of Amgen from $208.00 to $202.00 and set a “conviction-buy” rating for the company in a research report on Monday, March 20th. Vetr raised shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 target price for the company in a research report on Monday, March 27th. Jefferies Group LLC reissued a “hold” rating and set a $180.00 target price on shares of Amgen in a research report on Monday, May 22nd. Cann reissued a “positive” rating and set a $189.00 target price on shares of Amgen in a research report on Wednesday, March 15th. Finally, Leerink Swann reissued a “market perform” rating and set a $161.00 target price on shares of Amgen in a research report on Thursday, June 22nd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $185.65.

Amgen (NASDAQ AMGN) opened at 173.32 on Monday. Amgen has a 52 week low of $133.64 and a 52 week high of $184.21. The stock has a market cap of $127.46 billion, a price-to-earnings ratio of 16.46 and a beta of 1.35. The firm’s 50-day moving average is $162.22 and its 200 day moving average is $162.64.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating the Zacks’ consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the company posted $2.90 EPS. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. On average, equities research analysts expect that Amgen will post $12.43 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Amgen Inc. (AMGN) Stock Rating Reaffirmed by Morgan Stanley” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/10/amgen-inc-amgn-earns-overweight-rating-from-morgan-stanley.html.

In related news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. M. Kraus & Co raised its stake in Amgen by 8.3% in the second quarter. M. Kraus & Co now owns 2,591 shares of the medical research company’s stock valued at $446,000 after buying an additional 198 shares in the last quarter. Laurel Grove Capital LLC raised its stake in Amgen by 71.9% in the second quarter. Laurel Grove Capital LLC now owns 3,467 shares of the medical research company’s stock valued at $597,000 after buying an additional 1,450 shares in the last quarter. Appleton Partners Inc. MA raised its stake in Amgen by 3.3% in the second quarter. Appleton Partners Inc. MA now owns 17,180 shares of the medical research company’s stock valued at $2,959,000 after buying an additional 550 shares in the last quarter. Portland Global Advisors LLC raised its stake in Amgen by 0.3% in the second quarter. Portland Global Advisors LLC now owns 15,071 shares of the medical research company’s stock valued at $2,596,000 after buying an additional 45 shares in the last quarter. Finally, Johanson Financial Advisors Inc. raised its stake in Amgen by 1.5% in the second quarter. Johanson Financial Advisors Inc. now owns 2,100 shares of the medical research company’s stock valued at $362,000 after buying an additional 32 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.